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1. Introduction {#jia225072-sec-0005}
===============

Cobicistat is a potent and selective human CYP3A inhibitor without anti‐HIV activity showing a lower potential for undesirable drug‐drug interactions when compared to ritonavir (rtv) [1](#jia225072-bib-0001){ref-type="ref"}. When darunavir (DRV) 800 mg was boosted with cobicistat 150 mg (DRV~cobi~) once daily in healthy volunteers, DRV exposure was within the limits of bioequivalence for *C* ~max~ and AUC~24h~ compared to DRV~rtv~, but DRV C~trough~ were about 30% lower [2](#jia225072-bib-0002){ref-type="ref"}. This difference may not be clinically relevant for combined antiretroviral therapy (cART) since DRV~cobi~ has shown similar virological efficacy as DRV~rtv~ when administered in combination with two nucleos(t)ide analogue reverse‐transcriptase inhibitors (NRTIs) [3](#jia225072-bib-0003){ref-type="ref"}, [4](#jia225072-bib-0004){ref-type="ref"}. However, it remains unclear whether this is also true for DRV~cobi~ when given as monotherapy (mtDRV~cobi~).

Data derived from both clinical trials and real‐life practice suggest that most subjects with long‐lasting virological suppression maintain undetectable viraemia 48 to 96 weeks after switching to DRV~rtv~ monotherapy (mtDRV~rtv~). However, mtDRV~rtv~ is less effective than cART, as transient detectable viral loads (blips) are more frequent [5](#jia225072-bib-0005){ref-type="ref"}, [6](#jia225072-bib-0006){ref-type="ref"}, [7](#jia225072-bib-0007){ref-type="ref"}, [8](#jia225072-bib-0008){ref-type="ref"}. Since 2009, protease inhibitor (PI)‐based monotherapy is considered as a simplification option in both the Spanish and European guidelines for the use of antiretroviral agents in HIV‐1‐infected adults without history of failure on prior PI‐based therapy and who have had viral load \<50 copies/mL for more than 6 months [9](#jia225072-bib-0009){ref-type="ref"}, [10](#jia225072-bib-0010){ref-type="ref"}. In the clinical practice, DRV~rtv~ is currently being replaced by DRV~cobi~, but there are no data about the effectiveness of mtDRV~cobi~ and whether a lower DRV C~trough~ could impacts on efficacy or an increase in the numbers of blips. The aim of this study was to evaluate the efficacy of mtDRV~cobi~ in the daily clinical practice, to analyse the relationship between pharmacokinetic parameters and virological failure, and to compare it with historical data on mtDRV~rtv~.

2. Materials and methods {#jia225072-sec-0006}
========================

This prospective observational study was carried out at the Virgen del Rocío University Hospital~~s~~ in Spain. All subjects who maintained virological suppression ≥6 months and who switched to mtDRV~cobi~ once daily from January 2015 to January 2016 were included. Subjects with previous virological failure (VF) while on a PI‐containing regimen were included if the genotypic resistance tests showed no major (I47V, I50V, I54M/L, L76V and I84V) or ≤3 minor resistance mutations associated with reduced susceptibility to DRV according to the 2014 International AIDS Society criteria [11](#jia225072-bib-0011){ref-type="ref"}. The prescription of mtDRV~cobi~ was based on the criteria of the attending physicians as part of their daily clinical practice based on the encouraging results of several clinical trials [12](#jia225072-bib-0012){ref-type="ref"}, [13](#jia225072-bib-0013){ref-type="ref"}, [14](#jia225072-bib-0014){ref-type="ref"}, [15](#jia225072-bib-0015){ref-type="ref"}, [16](#jia225072-bib-0016){ref-type="ref"}, [17](#jia225072-bib-0017){ref-type="ref"} and personal experience on boosted‐PI monotherapy [18](#jia225072-bib-0018){ref-type="ref"}, [19](#jia225072-bib-0019){ref-type="ref"}, [20](#jia225072-bib-0020){ref-type="ref"}, [21](#jia225072-bib-0021){ref-type="ref"}, [22](#jia225072-bib-0022){ref-type="ref"}, [23](#jia225072-bib-0023){ref-type="ref"}, [24](#jia225072-bib-0024){ref-type="ref"}, [25](#jia225072-bib-0025){ref-type="ref"}, [26](#jia225072-bib-0026){ref-type="ref"}, [27](#jia225072-bib-0027){ref-type="ref"}, [28](#jia225072-bib-0028){ref-type="ref"}, with the objective of avoiding toxicity associated with nucleoside analogues, increasing adherence, and to augment the cost‐effectiveness of therapy [29](#jia225072-bib-0029){ref-type="ref"}. Inclusion was not dependent on CD4^+^ T cell counts, hepatitis C virus (HCV) coinfection, laboratory parameters or the presence of viral blips during the previous 12 months.

In our hospital, mtDRV~cobi~ was not prescribed in case of pregnancy, hepatitis B coinfection or for concomitant use with drugs having potential adverse interactions with DRV~cobi~ pharmacokinetics [30](#jia225072-bib-0030){ref-type="ref"}. This study was conducted according to the principles of the Declaration of Helsinki and was approved by the Ethics Committee for Clinical Research of the Virgen del Rocío University Hospital. All subjects provided written informed consent to use their anonymized data and to perform plasma drug monitoring.

2.1. Endpoints, follow‐up and assessments {#jia225072-sec-0007}
-----------------------------------------

The primary clinical endpoint was treatment effectiveness, assessed as the percentage of subjects with virological suppression after 48 and 96 weeks according to intention‐to‐treat (ITT) analysis (non‐complete/missing = failure). Virological failure (VF) was defined as two consecutive confirmed plasma HIV‐RNA \>200 copies/mL, or a single HIV‐RNA level \>200 copies/mL if followed by a loss to follow‐up. A cut‐off level of 200 copies/mL was chosen as a more accurate measurement of VF since values \<200 copies/mL suffer high variability and the risk of emerging resistance is believed to be relatively low [31](#jia225072-bib-0031){ref-type="ref"}, [32](#jia225072-bib-0032){ref-type="ref"}. An additional estimation of virological failure rates using 50 copies/mL as criteria for VF was made to compare with other studies. As a secondary outcome, virological efficacy was assessed using on‐treatment (OT) analysis, where subjects who discontinue therapy for any reason, as well as those who are lost to follow‐up, are not considered. In addition, a pharmacological sub‐study was performed in which the association between plasma levels and treatment outcome was analysed. As reference, efficacy data and pharmacological results were compared with those of a historical cohort of 150 subjects who started mtDRV~rtv~ at our centre [8](#jia225072-bib-0008){ref-type="ref"}.

Subject assessments were performed at baseline and every 3 months thereafter, including adherence (subject self‐report and pharmacy records), adverse events (AEs), biochemical and haematological profiles, flow cytometric counts of CD4^+^ T cells and plasma HIV‐RNA levels (COBAS AmpliPrep/COBAS TaqMan HIV‐1 test, version 2.0). AEs and abnormal laboratory findings were evaluated according to a standardized toxicity grade scale (AIDS Clinical Trials Group) [33](#jia225072-bib-0033){ref-type="ref"}. Genotypic resistance tests were performed on subjects with VF when viral load levels were sufficient. Subjects who missed two consecutive scheduled visits were considered lost to follow‐up.

2.2. Blood sampling and determination of DRV concentrations {#jia225072-sec-0008}
-----------------------------------------------------------

Blood samples were drawn 24 h (±30 min) after the previous DRV~cobi~ dose taken after standard breakfast and processed within an hour after collection. Plasma was separated and stored at −80°C until assayed. Separation was performed on a Phenomenex Luna C18 (5 μm, 150 × 2.0 mm) analytical column. The mobile phase was composed of 2 mM ammonium acetate 0.1% formic acid and acetonitrile 0.1% formic acid. DRV was extracted from the plasma by protein precipitation, using acetonitrile containing a deuterated internal standard. Plasma DRV concentrations were determined using LC--MS/MS based on an adapted method [34](#jia225072-bib-0034){ref-type="ref"} with standard curves that were highly linear over the range of 50 to 10,000 ng/mL and an intra‐ and inter‐assay precision and accuracy of \<15%.

2.3. Statistical analysis {#jia225072-sec-0009}
-------------------------

Categorical and quantitative variables were compared using the χ^2^ test, Student\'s t‐test or Mann‐Whitney nonparametric test, according to their distribution. Time‐to‐event analyses were performed by Kaplan‐Meier survival curves. Both the intra‐ and inter‐subject variability in drug concentrations was measured using the coefficients of variation (CV) of the available values from each subject. Pharmacokinetic data were compared with those of the historical DRV~rtv~ cohort [8](#jia225072-bib-0008){ref-type="ref"}, where 587 samples from 119 subjects were analysed. Statistical analyses were performed using the IBM software (SPSS v. 23.0, Chicago, USA), and *p*‐values \<0.05 were considered significant.

3. Results and discussion {#jia225072-sec-0010}
=========================

A total of 234 subjects were included in the study with a median follow‐up of 96 weeks (IQR, 58 to 96; range, 24 to 96). Baseline characteristics are described in Table [1](#jia225072-tbl-0001){ref-type="table-wrap"}. Before switching to mtDRV~cobi~, 175 (74.8%) subjects were on monotherapy as maintenance regimen (144 on DRV~rtv~, and 31 on LPV~rtv~), while 48 (20.5%) and 11 (4.7%) subjects were on triple and dual therapy, respectively.

###### 

Baseline characteristics of the study population (n = 234)

  Parameter                                              Value
  ------------------------------------------------------ ----------------------
  Male, no. (%)                                          178 (76.1)
  Age (years), M (IQR)                                   49.5 (43 to 54)
  Weight (kg), M (IQR)                                   71.5 (62.5 to 83)
  BMI kg/m^2^, M (IQR)                                   25 (22 to 27)
  Nadir CD4^+^/μL, M (IQR)                               150 (52 to 248)
  CD4^+^ T cells/μL, M (IQR)                             662 (512 to 837)
  Zenith HIV‐RNA log~10~ copies/mL, M (IQR)              4.8 (4.1 to 5.3)
  Previous CDC C stage, no (%)                           66 (28.2)
  Risk factor for HIV, no. (%)                           
  Previous intravenous drug use                          96 (41)
  Homosexual contact                                     62 (26.5)
  Heterosexual contact                                   66 (28.2)
  Other                                                  10 (4.3)
  Chronic hepatitis C, no. (%)                           40 (17.1)
  Cirrhosis no. (%)                                      8 (3.4)
  Months on treatment, M (IQR)                           141 (92 to 195)
  Months with undetectable HIV‐RNA, M (IQR)              85 (50 to 119)
  Presence of blips in the previous 12 months, no. (%)   22 (9.4)
  Previous failure on protease inhibitors, n (%)         154 (65.8)
  Previous ART regimens                                  
  Monotherapy regimens                                   175 (74.8)
  DRV~rtv~ monotherapy                                   144 (61.5)
  LPV~rtv~ monotherapy                                   31 (13.2)
  Dual therapy regimens                                  11 (4.7)
  ATV + 3 TC                                             7 (2.9)
  DRV~rtv~ + 3TC                                         1 (0.42)
  Others                                                 3 (1.28)
  Triple therapy regimens                                48 (20.5)
  CKD‐EPI mL/min/1.73 m^2^, M (IQR)                      99.1 (83.2 to 105.8)
  CKD‐EPI \< 60 mL/min/1.73 m^2^, no. (%)                3 (1.2)

M (IQR), Median (interquartile range), CDC, Centers of Disease Control; HCV, hepatitis C virus; ART, antiretroviral therapy; DRV~rtv~, ritonavir‐boosted darunavir; LPV~rtv~, ritonavir‐boosted lopinavir; ATV, atazanavir; 3TC, lamivudine; CKD‐EPI, Chronic Kidney Disease Epidemiology Collaboration.

John Wiley & Sons, Ltd

One hundred and fifty‐four (65.8%) subjects had an earlier VF while receiving non‐boosted PI, including 30 (12.8%) subjects who had experienced a previous VF on a DRV~rtv~‐based regimen caused by treatment withdrawal. Genotypic resistance tests before switching to mtDRV~cobi~ was available for 127 subjects who had shown VF, including all 30 subjects who had failed to DRV~rtv~, showing no major resistance mutations to DRV in any case.

3.1. Efficacy and safety {#jia225072-sec-0011}
------------------------

The Kaplan‐Meier estimations of treatment effectiveness by ITT analysis were 82.5% (CI~95~, 77.6 to 87.3) and 67.8% (CI~95~, 61.8 to 73.7) at week 48 and 96, respectively, while the historical control data with mtDRV~rtv~ were 82.7% (CI~95~, 76.7 to 88.7) and 67.6% (CI~95~, 60.0 to 75.2) respectively. In an OT analysis, the values in the present cohort were 94.4% (CI~95~, 91.4 to 97.3) and 86.9% (CI~95~, 78.0 to 87.7), respectively, and 94.4% (CI~95~, 91.4 to 97.3) and 83.6% (CI~95~: 77.2 to 90.0) in the historical cohort (Figure [1](#jia225072-fig-0001){ref-type="fig"}). The estimations of virological failure rates using 50 copies/mL as criteria for virological failure are displayed in Table [2](#jia225072-tbl-0002){ref-type="table-wrap"}.

![Kaplan‐Meier estimations of efficacy by on‐treatment (OT) and by intention‐to‐treat (ITT) at 48 and 96 weeks.](JIA2-21-e25072-g001){#jia225072-fig-0001}

###### 

Kaplan‐Meier estimations of the efficacy of mtDRV~cobi~ using HIV‐RNA \>50 copies/mL x2 or \>50 x1 followed by loss to follow‐up as definition for virological failure

  ---------------------------------------------------------------------------------------------
  Virological failure definition              Virological efficacy     
  ------------------------------------------- ------------------------ ------------------------
  HIV‐RNA \>200 copies/mL x2\                 94.4%\                   86.2%\
  or \>200 x1 followed by loss to follow‐up   (CI~95~, 91.4 to 97.3)   (81.7 to 90.6)

  HIV‐RNA \>50 copies/mL x2\                  88.9%\                   81.4%\
  or \>50 x1 followed by loss to follow‐up    (CI~95~: 84.8 to 92.9    (CI~95~: 76.4 to 86.3)
  ---------------------------------------------------------------------------------------------

John Wiley & Sons, Ltd

Twenty‐seven subjects (11.5%) had VF as defined by the protocol with a median plasma HIV‐RNA at failure of 1450 copies/mL (IQR, 244 to 5707). Eleven of these subjects were on cART before switching to monotherapy, 14 subjects were on monotherapy regimens and two on dual therapy.

There was no significant difference in the VF rates among those subjects with and without an earlier VF while on a PI‐based regimen (9.7% vs. 15.0% respectively; *p *=* *0.263). Furthermore, 60 (25.6%) subjects had a blip episode while on mtDRV~cobi~, whereas this figure was 27.6% in the historical cohort on mtDRV~rtv~ (*p *=* *0.713). After 6 months, 26 out of 27 subjects who experienced a VF regained virological control either by adding one (n* *=* *11) or two (n* *=* *8) NRTIs to mtDRV~cobi~ or switching to another triple therapy (n* *=* *8). Other treatment failures were due to AEs (n* *=* *7; grade 2 hypercholesterolaemia, 1; grades 1 and 3 hypertriglyceridaemia, 2; and grade 1 gastrointestinal disorder, 4), loss to follow‐up or treatment dropout (n* *=* *10), switching to another regimen by physician decision without VF criteria (n* *=* *6), death unrelated to treatment (n* *=* *1),and other reasons not related to the treatment, such as imprisonment, pregnancy, drug interactions or relocation (n* *=* *22). All these subjects had an undetectable viral load at the time of the last available HIV‐RNA assessment.

Regarding the CD4^+^ T cell counts, the mean increase from baseline to week 96 was 75 cells/mL (CI~95~, 25 to 125). Aminotransferase level elevations throughout the follow‐up occurred in 6/40 (15%) subjects with chronic hepatitis (grades 1, 5; grades 2, 1) and in 17/194 (8.8%) subjects without chronic hepatitis (grades 1, 12; grades 2, 2; grades 3, 1). All aminotransferase elevations were transient and improved without treatment modification. No significant changes were found in the lipid profiles. Overall, the mean changes in fasting total cholesterol and triglycerides in the subjects who completed 96 weeks were 5 mg/dl (CI~95~,−3 to 13) and −17 mg/dL (CI~95~, −42 to 7) (*p*‐values \>0.1).

3.2. Pharmacokinetics of DRV {#jia225072-sec-0012}
----------------------------

A total of 135 DRV determinations were performed in plasma samples derived from 83 subjects throughout the follow‐up period. The median of the plasma samples per subject was 2 (range, 1 to 2). Plasma DRV C~trough~ was lower for mtDRV~cobi~ (median, 1305 ng/mL; IQR, 652 to 2058; range, 150 to 5895) as compared to data of subjects on DRV~rtv~, (median, 1710 ng/mL; IQR, 1160 to 2210; range, 200 to 3838) (*p *=* *0.05). We did not observe relationships between plasma DRV concentrations and weight (*r* ^2^ = 0.106; *p *=* *0.340) or body mass index (*r* ^2^ = 0.127; *p *=* *0.282), nor differences in plasma DRV C~trough~ according to gender, the presence of chronic hepatitis, cirrhosis or renal dysfunction. The median intra‐subject variability was 27.4% (IQR, 18.5 to 54.0; range, 12.8 to 130.5) for subjects on mtDRV~cobi~, and 38.8% (IQR, 25.4 to 59.1; range, 3.7 to 213.1) for subjects on mtDRV~rtv~. Inter‐subject variability for subjects with more than one DRV C~trough~ determination (n = 57) was 92.1% for those on mtDRV~cobi~ and 43.6% for those on mtDRV~rtv~, respectively. We did not find any statistically significant difference between DRV plasma concentration and subjects with and without VF, median; 738 ng/mL (IQR; 467 to 2037) and 1378 ng/mL (IQR; 705 to 2185) (*p *=* *0.710) respectively.

Although somewhat less effective than triple therapy, more than 90% of virologically suppressed subjects switching to mtDRV~rtv~ maintained virological control in the clinical practice, even in subjects with previous VF‐ on PI‐based regimens when no major resistance mutations for DRV were present [7](#jia225072-bib-0007){ref-type="ref"}, [8](#jia225072-bib-0008){ref-type="ref"}. As it has been reported from various studies, monotherapy has a higher frequency of blips, although this has not been related to a higher frequency of VF. Moreover, in patients who failure on monotherapy with boosted PI, no resistance mutations have been found, and the introduction of analogues has been enough to control the infection again [35](#jia225072-bib-0035){ref-type="ref"}, [36](#jia225072-bib-0036){ref-type="ref"}, [37](#jia225072-bib-0037){ref-type="ref"}. These results, the benefits of regimens lacking the toxicity of nucleoside analogues, the low incidences and grades of the AEs, and to save up in antiretroviral drug costs [29](#jia225072-bib-0029){ref-type="ref"} support the use of mtDRVrtv in clinical practice.

Recently, Ciaffi et al. reported a rate of virological failure as high as 21% at week 48 with DRV‐ or lopinavir‐based monotherapy as second‐line maintenance treatment for HIV‐1‐infected patients in sub‐Saharan Africa [38](#jia225072-bib-0038){ref-type="ref"}. Almost certainly these results were due to the fact that only 80% of the patients had a viral load \<50 copies/mL at baseline.

Currently, DRV~rtv~ is being replaced by DRV~cobi~ in spite of an about 30% lower DRV C~trough~ as observed in healthy volunteers. To the best of our knowledge, this is the first study addressing the effectiveness of mtDRV~cobi~. Our results show that the DRV C~trough~ is about 22% lower for DRV~cobi~ than the concentrations observed from our historical data with mtDRV~rtv~. However, these concentrations remain above sixfold the protein binding‐adjusted EC~90~ for wild‐type HIV‐1 (200 ng/mL) and above threefold the protein binding‐adjusted EC~50~ for resistant HIV‐1 (550 ng/mL) [39](#jia225072-bib-0039){ref-type="ref"} in most subjects. Two and 13 subjects had a C~trough~ below of 200 and 550 ng/mL, respectively, of whom only two subjects had VF, presenting a DRV C~trough~ of 463.82 and 353.83 ng/mL. While the intra‐subject variability in DRV C~trough~, was similar for both regimens, the inter‐subject variability appeared to be higher in the case of DRV~cobi~, although the number of subjects is insufficient to draw conclusions on this issue. Nonetheless, the effectiveness was similar to that observed previously with mtDRV~rtv~ [7](#jia225072-bib-0007){ref-type="ref"}, [8](#jia225072-bib-0008){ref-type="ref"}. The frequency of AEs in the present study was below 2%, which can in part be explained by the large proportion of subjects who were on a DRV~rtv~‐based regimen before switching to mtDRV~cobi~.

Our study has some limitations. First, blood samples for drug monitoring in the present study was not as frequent as in the earlier study, as in the last years the blood samples for the control of the HIV infection can be collected in primary health centres from where the samples are transferred in the same morning to our hospital. However, the analysis of pharmacokinetics was not the primary aim of the present work and still a considerably high proportion of patients representing the overall population could be analysed. Furthermore, although the number of subjects with VF are low, the data obtained from those subjects who were virologically suppressed show that the lower DRV concentrations observed when boosting with cobicistat appear not to impact on treatment outcome. Second, data from a previous cohort on mtDRV~rtv~ was used as reference, since the present study is a prospective observational study that does not include controls. Still, both data sets were obtained from one single cohort including subjects seen at one single centre and by the same physicians, following a unique protocol. Therefore, the data can be regarded as comparable.

4. Conclusion {#jia225072-sec-0013}
=============

According to the data obtained in our study, it seems that the change ritonavir to cobicistat does not affect the efficacy of monotherapy with DRV, regardless of the lower plasma C~trough~ achieved.
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